Rohto Pharmaceutical
4527.TPharmaceutical
Financials · Consolidated
| Fiscal year ended | 2026-03 | 2025-03 | 2024-03 | 2023-03 | 2022-03 | 2021-03 |
|---|---|---|---|---|---|---|
| Revenue | ¥343.7bn | ¥308.6bn | ¥270.8bn | ¥238.7bn | ¥199.6bn | ¥181.3bn |
| Operating income | ¥41.1bn | ¥38.2bnr | ¥40.0bn | ¥34.0bn | ¥29.0bnr | ¥23.0bn |
| Ordinary income | ¥48.0bn | ¥39.7bnr | ¥42.4bn | ¥35.6bn | ¥28.8bnr | ¥23.9bn |
| Net income (owners) | ¥34.2bn | ¥30.8bnr | ¥30.9bn | ¥26.4bn | ¥21.1bnr | ¥16.7bn |
| Total assets | ¥485.8bn | ¥437.0bnr | ¥346.2bn | ¥309.7bn | ¥274.9bnr | ¥226.1bn |
| Net assets / equity | ¥320.2bn | ¥280.7bnr | ¥247.0bn | ¥215.1bn | ¥184.0bnr | ¥156.6bn |
| Operating cash flow | ¥47.8bn | ¥36.9bn | ¥34.2bn | ¥30.9bn | ¥27.3bn | ¥20.0bn |
| EPS (basic) | ¥151.56 | ¥135.38r | ¥135.61 | ¥115.62 | ¥92.61r | ¥73.39r |
From EDINET filings. Select any figure to open the report it came from. r = changed in a later filing (the report page shows the original). — = not reported in the filings structured so far.
Reports · 4
| Period | Form | Figures |
|---|---|---|
| 2023-04-01 → 2023-12-31 | Quarterly Q3 | 52 figures · EDINET |
| 2023-04-01 → 2023-09-30 | Quarterly Q2 | 76 figures · EDINET |
| 2023-04-01 → 2023-06-30 | Quarterly Q1 | 50 figures · EDINET |
| 2022-04-01 → 2023-03-31 | Annual | 214 figures · EDINET |
22 more reports are still being processed.
Segments · FY ended 2026-03
| Segment | External sales | Profit |
|---|---|---|
| America | ¥21.6bn | ¥1.7bn |
| Asia | ¥125.3bn | ¥15.0bn |
| Europe | ¥23.9bn | ¥1.0bn |
| Japan | ¥169.3bn | ¥22.1bn |
| Other segments | ¥3.6bn | ¥383m |
| Adjustments & eliminations | — | ¥846m |
| Total | ¥340.1bn | ¥39.9bn |
| Total | ¥343.7bn | ¥40.3bn |
Segment names from EDINET member IDs; not mapped to a common taxonomy.